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Background: To evaluate bone status in children born from mothers followed for autoimmune diseases and
treated during pregnancy with low molecular weight heparin (LMVH) and/or prednisone.
Findings: History, physical examination, laboratory tests and phalangeal ultrasonography were performed.
Demographic, clinical, and laboratory data were entered into a customized database, and results were analyzed
with SPSS software. In children whose mothers were treated with LMWH, we retrieved dried blood spots taken for
newborn screening, and analyzed the presence of heparin with tandem mass spectrometry.
We enrolled 27 females and 14 males born from 31 mothers with SLE or connective tissue diseases. These women
were continuously treated during pregnancy with LMWH (n = 10), prednisone (n = 16), or both (n = 15). Bone
ultrasound revealed low values (≤3 centile for age) in ten patients. In a multistep regression analysis, age at
examination resulted the single predictor of low ultrasound values (p < 0.004). Tandem mass spectroscopy failed to
determine traces of heparin in newborn blood.
Conclusions: Children born from mothers with autoimmune diseases are at risk to develop reduced bone mass.
The administration of LMWH and of prednisone seems to be safe with regard to children’s bone health.
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Pregnancy is characterized by the combination of a
procoagulant state, meant to avoid massive maternal
bleeding during delivery, and venous stasis caused by ven-
ous dilation and compression by the gravid uterus [1].
Thus, pregnant women are at higher risk of developing
thromboembolic complications; this risk is further
increased among women suffering from prothrombotic
conditions such as systemic autoimmune disorders [2].
Among patients affected with connective tissue diseases,
thrombosis is a major issue in women with systemic lupus
erythematosus (SLE), and in those with antiphospholipid* Correspondence: ilaria.pagnini@gmail.com
1Department of Pediatrics, University of Florence, AOU Meyer, Rheumatology
Unit, Viale Pieraccini 24, 50139 Florence, Italy
Full list of author information is available at the end of the article
© 2014 Pagnini et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.syndrome (APL). Thus thromboprophylaxis with low-
molecular-weight heparins (LMWH) is advised, although
the potential fetal and maternal toxicity of antithrombotic
drugs and their impact on delivery still needs to be fully
elucidated. Concomitant treatment with low dose aspirin
is generally also recommended [3]. Moreover, in patients
with connective tissue diseases, corticosteroids such as
prednisone and prednisolone are usually administered in
order to control maternal disease flares.
Bone health is influenced by genetic and environmental
factors, some of which concern early childhood or even
prenatal life [4-6]. In this regard, chronic maternal dis-
ease and maternal treatments could potentially have an
impact on bone status of their offspring.
Both long-term LMWH therapy and corticosteroids
may be associated with osteopenia in mothers, althoughLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the risk of drug-induced osteoporosis during pregnancy
[7-11]. Although it has been shown that LMWHs do not
seem to cross the placenta [12] and that they seem to be
safe for the fetus, and although it is known that prednis-
one and prednisolone are mostly inactivated by placental
hydroxilase, their effects on bone status in children born
from mothers treated with these drugs during pregnancy
are currently unknown.
The aim of our study was to evaluate bone status in a
cohort of children born from mothers affected by systemic
autoimmune disorders and treated during pregnancy with




Our study group included 41 children born from 31
mothers affected by systemic autoimmune diseases, who
were treated with LMWH and/or prednisone throughout
pregnancy. All mothers had been prospectively followed
at the Rheumatology Unit of University of Siena, Italy
from 2000 to 2011. Their medical records were reviewed
and relevant demographic, clinical and laboratory data
were collected into a customized database. Families were
contacted and agreed to participate in the study. All chil-
dren were evaluated at the Pediatric Rheumatology Unit
of Meyer Children’s Hospital, Florence, Italy. A complete
history and physical examination was performed in all
cases. Body mass index (BMI) was calculated with the
following formula: weight (kg)/height (m)2. Relevant data
were also entered into the database. Informed consent by
parents, and Institutional Ethics Committee approval
were obtained (Policlinico “Le Scotte”, Siena, Italy).
Laboratory assessment
In all children complete blood count, C-reactive pro-
tein, serum calcium, phosphorus and creatinine were
determined at clinic visit. Bone formation markers
(bone alkaline phosphatase, osteocalcin), a bone re-
sorption marker [serum carboxyterminal telopeptide of
type I collagen (ICTP)], serum vitamin D levels (25-OH
Vit. D), as well as autoantibodies [antinuclear anti-
bodies (ANA), and anticardiolipin antibodies (aCL)]
were also determined. Bone metabolism markers and
aCL were measured by ELISA, while ANA were deter-
mined by indirect immunofluorescence.
Bone status assessment
Phalangeal ultrasonography (DBM Sonic 1200 machine,
IGEA, Carpi, Italy) was performed in all patients. The
machine was calibrated at the start of each session. The
measurements were made by one trained operator (LC)
in order to avoid interoperator errors. A phantom armwas used to calibrate measures and the procedures were
always performed in standard room temperature and by
the same operator (LC).
The technology is based on the transmission of ultra-
sound through the proximal phalanges, using a gel based
device. The device calculates the amplitude-dependent
speed of sound (AD-SoS) and averages the AD-SoS values
for the four phalanges measured, and the intra-operator
errors are less than 1% [13,14]. The DBM Sonic device
consists of two spring-loaded calipers, which are attached
to probes. The probes were positioned medio-laterally on
the proximal phalanx. An ultrasound pulse is transmitted
from one probe and received by the other after passing
through the phalanx. A mean amplitude-dependent speed
of sound value is automatically generated on a screen that
reflects the quality of the bone the ultrasound has passed
through. The calipers are adjusted around the phalanx to
give an optimal signal. Values below the given threshold
for soft tissue measurement were excluded. The second to
fifth fingers of each hand were measured to give a mean
AD-SoS value for each hand. This was compared to the
manufacturer’s database to derive a Z score that reflected
the standard deviation from the age- and sex-matched
mean value; [15] results were expressed as percentiles.
Statistical analysis
All results are expressed as mean ± standard deviation
(SD) or median (range). Quantitative ultrasound (QUS)
percentile values (spanning between 3rd and 97th per-
centiles) were provided by the manufacturer, and each
one was also adjusted for the BMI values at the time of
bone ultrasound determination.
Mann–Whitney U-test, or Fisher’s exact test, were used
as appropriate. Nonparametric tests were used, where
necessary, due to the small size of our groups and to the
skewness of data. Levels of p < 0.05 were considered
statistically significant. Analyses were performed on SPSS
package for Windows, version 13.0 (SPSS, Inc., Chicago,
IL, USA).
The Spearman rank correlation test was used to deter-
mine correlation coefficients between QUS percentiles
and the following variables: gender, age, weight, height,
BMI, family history of autoimmune diseases, maternal
diagnosis, maternal treatment during pregnancy (both as
categorical variable, i.e. receiving treatment during preg-
nancy or not, as well as specific treatment received), being
sibling or only child, intrauterine complications, APGAR
score, cesarean section, length, weight and cranial
circumference at birth, prematurity, formula or breast
feeding, growth and development during the first year of
life, vitamin D supplementation, vitamin D levels, osteo-
calcin and bone alkaline phosphatase serum levels.
Multiple stepwise regression, with BMI values at the
time of QUS evaluation acting as covariate, was performed
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ently; thus the predictors used in the final model were
those showing a significant correlation in the univariate
analysis.
Sample preparation for mass spectrometry analysis
In order to exclude transplacental passage of LMWH,
we were able to retrieve dried blood spots (DBS), taken
after 48 hours of life for newborn screening purposes,
from children whose mothers received LMWH during
pregnancy and we investigated the possible presence of
heparin with a new liquid chromatography tandem mass
spectrometry method.
Sample preparation was performed according to pub-
lished and validated method for glycosaminoglycans
measurement with slight modifications [16]. Heparin
was measured as methylated disaccharides after metha-
nolysis. Methanolysis was performed on extracted DBS
(3.2 mm containing about 3.4 μL of blood) by using
200 μL HPLC water. For heparin, among all degradation
products detected, we chose one particular disaccharide
in order to obtain the highest specificity by liquid chro-
matography and mass spectrometry. The samples were
measured using analytical HPLC coupled to a QTRAP
5500 (AB SCIEX, Toronto, Canada) equipped with the
TurboIonSpray source operated in positive ion mode.
The capillary voltage of the mass spectrometer was set
to 5500 V, the “turbo” gas flow was 10 L/min of air
heated at 550°C. The following transitions were moni-
tored in MRM mode (Multiple Reaction Monitoring):
m/z 384.2.1 > 162.1. Optimal CE (Collision Energy) and
CXP (Collision Cell Exit Potential) were found at 20
Volts and 13 Volts respectively. The resulting DP
(Declustering Potential) was +40 Volts. The quantita-
tion experiments were undertaken with an external
calibration by using a Series 1290 Infinity LC System
(Agilent Technologies, Waldbronn, Germany) HPLC
Capillary Pump coupled to an Agilent Micro ALS auto-
sampler, both being fully controlled from the QTRAP
5500 data system. Liquid chromatography was per-
formed using a Kinetek 2.6 μm C18 100 Å 7.5 × 3 mm4
HPLC column (Phenomenex, Andover, USA). Column
flow was 0.2 mL/min using a water/acetonitrile (20:80)
and 0.05% formic acid in an isocratic elution system.
The eluent from the column was directed to the
TurboIonSpray probe without split ratio. Three μL of
the extracted sample were injected for the HPLC-MS/
MS experiments. System control and data acquisition
were performed with Analyst 1.5.1 software including
the “Explore” option (for chromatographic and spectral
interpretation) and the “Quantitate” option (for quanti-
tative information generation). Calibration curves were
constructed with the Analyst Quantitation program
using a linear least-square non-weighted regression.Findings
We enrolled 27 girls and 14 boys (mean age at clinic visit
5 years and 10 months, range 9 months- 12 years), born
from 31 mothers with systemic autoimmune diseases (there
were 9 enrolled mothers who had two pregnancies during
which prednisone and/or LMWH were administered).
All mothers had been continuously treated during all
pregnancies with daily LMWH in 10 cases, prednisone in
15 cases, or both in 15 cases. There were 11 preterm de-
liveries (gestational age < 37 weeks), in 7 women affected
by SLE, 3 by primary antiphospholipid syndrome (PAPS)
and one by granulomatosis with polyangitis; fetal distress
was reported in 4 cases. Median birth weight was 2935 g,
range 520–3790. Eight newborns had neonatal complica-
tions: respiratory distress (n = 3), jaundice (n = 3), transi-
ent hypocalcemia and hypoxic-ischemic syndrome (n = 1
each). Breastfeeding for at least 6 months was reported in
12 cases; 37 children had received vitamin D supplemen-
tation (400 IU/day; 6/37 for 6 months, 31/37 for the first
year of life), and growth and development were within
normal limits. No history of fractures in mothers or chil-
dren was recorded.
In all children clinical examination was within normal
limits for age. Of note, 2 patients had alterations on pri-
mary teeth, with cavities and enamel abnormalities, but
without any damage on permanent teeth; one of these
babies was born from a mother with SLE treated with
LMWH and prednisone and the other one, with neo-
natal transient hypocalcemia, was born from a woman
with granulomatosis and polyangitis who had received
prednisone.
Table 1 shows main clinical, epidemiological, laboratory,
and instrumental results collected from both mothers and
their children.
Routine laboratory tests were in the normal range in all
cases. Despite previous routine supplementation, vitamin
D serum levels were in the normal range (>30 ng/ml) in
only 15/41 patients, while they were decreased in 26 chil-
dren; these had been exposed to LMWH (n = 6), prednis-
one (n = 12), and LMWH and prednisone (n = 8). Bone
formation and resorption markers were in all cases in the
normal range provided by our laboratory. Autoantibodies
(ANA, aCL IgM and IgG), at the moment of evaluation,
were present in 13 cases (9 children were ANA-positive,
and 4 aCL-positive), all born from mothers with the same
autoantibodies.
Bone ultrasound recorded QUS values ≤3 percentile for
age and gender in 10 children, 10 resulted between >3°
and ≤25° and all the other 21 showed a QUS percentile
value higher than 25°.
In univariate analysis, QUS percentile values showed a
significant correlation with age at examination (rs: 0.41,
p < 0.006), and osteocalcin values (rs: −0.32, p < 0.04). No
significant correlations were detected with the other
Table 1 Main clinical, epidemiological, laboratory and instrumental results collected from mothers with autoimmune diseases and their children

















BMI at visit QUS
(percentile)
1 a PAPS none Enoxiparin 2000 UI bid. Aspirin 38 None 7 yrs 6 mo 14.9 97
1 b PAPS none Enoxiparin 2000 UI bid. Aspirin 36 None 9 yrs 17.3 75
2 a Sjögren ANA Enoxiparin 2000 UI bid. None 40 None 8 yrs 9 mo 15.9 75
3 a SLE ANA, ENA Enoxiparin 2000 UI bid. Aspirin 30 + 4 None 5 yrs 1 mo 16.9 75-90
3 b SLE ANA, ENA Enoxiparin 2000 UI bid. Aspirin 36 + 5 None 2 yrs 16.1 < 3
4 a UCTD ANA, LAC Enoxiparin 2000 UI bid. Aspirin 39 + 4 None 6 yrs 2 mo 16.8 97
5 a PAPS ANA, ENA, LAC, aCL
IgM
Nadroparin 3800 UI daily Aspirin 39 + 4 None 5 yrs 3 mo 15.4 25
6 a Systemic Sclerosis ANA, aCL IgM Nadroparin3800 UI daily None 38 + 4 None 6 yrs 4 mo 16.1 < 3
6 b Systemic Sclerosis ANA, aCL IgM Nadroparin3800 UI daily None 38 None 9 yrs 4 mo 19.5 < 25
7 a SLE ANA, ENA, LAC, aCL
IgM, aCL IgG
Enoxiparin 4000 UI daily Aspirin 40 None 3 yrs 9 mo 17.2 < 3
8 a SLE ANA, aCL IgM Methylprednisolone 4 mg daily None 40 None 2 yrs 3 mo 17.1 > 97
9 a MCTD ANA, ENA Methylprednisolone 4 mg daily None 40 None 6 yrs 9 mo 15.8 75
10 a Granulomatosis
with polyangitis
ANA, ANCA Prednisone 15 mg daily IVIG 40 None 7 yrs 9 mo 16.5 25
10 b Granulomatosis
with polyangitis
ANA, ANCA Prednisone 15 mg daily IVIG 40 None 9 yrs 24 75
11 a SLE ANA, anti-DNA, aCL
IgG
Prednisone 25 mg daily IVIG 36 Post-partum
bleeding
8 yrs 3 mo 14.4 50
12 b SLE ANA, ENA, anti-DNA,
aCL IgG, aCL IgM
Prednisone 25 mg daily Aspirin 37 + 1 None 1 yrs 4 mo 16.4 25
13 a SLE ANA Prednisone 25 mg daily None 36 + 4 None 9 yrs 3 mo 16.7 50
13 b SLE ANA Prednisone 25 mg daily None 39 None 10 yrs 7 mo 18.9 75
14 a SLE ANA Prednisone 5 mg daily Aspirin 40 None 5 yrs 5 mo 15.4 50
15 b Sjögren ANA, ENA Prednisone 5 mg daily None 40 None 2 yrs 4 mo 12.4 50
16 a RA None Prednisone 5 mg daily None 39 None 12 yrs 14.5 25
16 b RA None Prednisone 5 mg daily None 40 None 4 yrs 5 mo 14 75
17 a SLE ANA, ENA, anti-DNA Prednisone 5 mg daily Aspirin 40 None 6 yrs 7 mo 12.2 25
17 b SLE ANA, ENA, anti-DNA Prednisone 5 mg daily Aspirin 40 None 3 yrs 9 mo 14 50
18 a UCTD ANA Methylprednisolone 5 mg daily None 39 + 5 None 1 yrs 16.2 < 3
















Table 1 Main clinical, epidemiological, laboratory and instrumental results collected from mothers with autoimmune diseases and their children (Continued)
20 a SLE ANA, anti-DNA Enoxiparin 4000 UI daily +
Prednisolone 4 mg daily
None 40 None 10 yrs 9 mo 25.7 75
21 a PAPS ACL IgG, anti-β2GPI Nadroparin 3800 UI daily +
Prednisone 5 mg daily
None 34 Mitralic
insufficiency
5 yrs 10 mo 15 25
21 b PAPS ACL IgG, anti-β2GPI Nadroparin3800 UI daily +
Prednisone 5 mg daily
None 34 Thrombocytopenia 9 yrs 7 mo 20.1 25-50
22 a SLE ANA, ENA, anti-DNA Nadroparin2850 UI daily +
Methylprednisolone 4 mg daily
None 38 None 11 yrs 3 mo 17.5 97
22 b SLE ANA, ENA, anti-DNA Nadroparin2850 UI daily +
Methylprednisolone 4 mg daily
None 36 + 5 None 5 yrs 5 mo 15.8 < 3
23 a MCTD ENA, aCL IgG Enoxiparin 4000 UI daily +
Prednisone 5 mg daily
None 37 + 1 None 9 mo 17.5 25
24 a SLE ANA, anti-DNA, aCL
IgG, anti-β2GPI
Enoxiparin 4000 UI daily +
Prednisone 10 mg daily
IVIG + Aspirin 40 None 10 yrs 25 < 3
24 b SLE ANA, anti-DNA, aCL
IgG, anti-β2GPI
Enoxiparin 4000 UI daily +
Prednisone 10 mg daily
IVIG + Aspirin 38 None 4 yrs 7 mo 15.4 < 3
25 a SLE ANA Enoxiparin 4000 UI daily +
Prednisone 25 mg daily
IVIG 40 None 1 yrs 5 mo 15.3 < 3
26 a UCTD ENA, aCL IgM Enoxiparin 4000 UI daily +
Prednisone 5 mg daily
None 36 None 10 yrs 9 mo 16.6 25
27 a UCTD ENA Enoxiparin 4000 UI daily +
Prednisone 5 mg daily
Aspirin 40 None 9 mo 16 97
28 a UCTD ENA, anti-β2GPI Enoxiparin 4000 UI daily +
Prednisone 5 mg daily
Aspirin 37 None 2 yrs 3 mo 19.1 97
29 a SLE ANA, ENA, LAC, anti-
DNA
Enoxiparin 4000 UI daily +
Prednisone 5 mg daily
None 40 None 5 yrs 11 mo 21.8 25
30 a SLE ANA Nadroparin2850 UI daily +
Prednisolone 8 mg daily
None 34 Hepatogestosis 11 mo 15.6 25
31 a SLE ANA Nadroparin2850 UI daily +
Prednisolone 8 mg daily
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during pregnancy. In multi-stepwise regression analysis,
weighted for BMI values at the time of bone ultrasound
determination, age at examination resulted the single
predictor of QUS values (multiple R = 0.44, multiple
adjusted R2: 0.18, p < 0.03) (Figure 1). In children with
low (≤3 percentile) QUS values, age at examination re-
sulted lower than in children with normal (>25 percent-
ile) QUS values (median, range: 27 months, 9–129 vs
79 months, 11–135, p < 0.006) (Figure 2).
Tandem mass spectroscopy performed on DBS failed
to determine traces of heparin in newborn blood.
Discussion
Many factors influence the accumulation of bone mineral
during childhood and adolescence, including heredity,
gender, diet, physical activity and endocrine status [17,18].
Measures for maximizing bone mineral acquisition,
particularly through physical activity and adequate dietary
calcium intake, are likely to affect the risk of fracture in
later life. In addition to these modifiable factors during
childhood, evidence has also shown that the risk of
fracture might be programmed during intrauterine life.
Maternal smoking, diet (particularly vitamin D defi-
ciency), physical activity, diseases and drugs also appear
to modulate bone mineral acquisition in intrauterine
life; furthermore, birthweight, weight in infancy, poor
childhood growth seem also to be linked to adult bone
mass [4-6,19,20].
Systemic autoimmune disorders largely affect women
during their reproductive age. Pregnancy in connective tis-
sue diseases has long been associated with poor obstetric












m R: 0.44 
m adj. R2: 0.18
Figure 1 The correlation of quantitative ultrasound (QUS)
percentile values with age, in months, at the time of the bone
ultrasound examination is shown in a multi-stepwise regression
analysis model (p < 0.03).For example, in SLE the risk of spontaneous abortion,
intrauterine fetal death, preeclampsia, intrauterine growth
restriction and preterm birth is common, such as an active
lupus nephritis in mothers [21]. So, a close follow-up is
mandatory, including repeated laboratory test and serial
ultrasonography in mothers, fetal surveillance tests, and
fetal echocardiography for mothers with SS-A (Ro) or SS-B
(La) antibodies [22]. In women with primary antiphospho-
lipid syndrome (PAPS) the risk of pregnancy complications
increases, including spontaneous miscarriages that typically
occur after 10 weeks of gestation, midpregnancy fetal
distress, intrauterine growth restriction, prematurity and
preeclampsia. In others autoimmune conditions, such as
rheumatoid arthritis (RA), systemic sclerosis and Sjögren
syndrome the risk of adverse pregnancy outcome is variable.
Moreover, women affected by autoimmune diseases are at
high risk of developing osteopenia, osteoporosis and frac-
tures through both disease-specific (chronic arthritis, re-
duced physical activity, induction of cytokines promoting
bone resorption, renal impairment, endocrine factors) and
nondisease-specific mechanisms (chronic anticoagulant,
glucocorticoid and immunosuppressive treatments, vita-
min D deficiency). Regarding thromboprophylaxis, sub-
cutaneous heparin is crucial against the risk of recurrent
thromboembolism or pregnancy loss [23]. Heparin and its
low molecular weight derivatives can be associated with
bone loss and an increased risk of fractures; however,
LMWHs seem to be less deleterious to bone than un-
fractionated heparin [24,25]. In addition, pregnancy by itself
and lactation may also predispose to osteopenia [26,27].
Unfractionated heparin is a large molecule, so it does
not cross the placenta. It seems not to be teratogenic and
not cause toxic fetal effects. Several studies have con-
firmed the safety and efficacy of LMWH during pregnancy
as well [28-34]. LMWHs also does not seem to cross the
placenta [30,31,33], thus with a fetal safety profile equiva-
lent to that of unfractionated heparin. However, the possi-
bility that unfragmented heparin or LMWH pass the
placental barrier to the fetus has been studied only indir-
ectly. Mätzsch et al. studied 21 women who had an abor-
tion by hysterotomy. Laboratory assessments included
assays of factor Xa inhibitory activity (XaI), antithrombin
III (ATIII) and a measurement of heparin-like substances
in plasma with a competitive binding assay. The authors
did not demonstrate any evidence for the passage of
heparin or LMWH across the placental barrier, further-
more no differences were detected whether unfragmented
heparin or LMWH had been given to the mothers [35]. In
another study [12], 14 women who were going to have an
early termination of pregnancy due to major fetal mal-
formations were given 40 mg of enoxaparin. Maternal
blood samples were drawn before and after the injection
of enoxaparin, while fetal blood samples were taken only
after the drug administration. Anti-IIa and anti-Xa
Figure 2 Age (in months) at the time of bone ultrasound examination in children with ≤3 percentile QUS values (white box) and in
children with >25° percentile QUS values (grey-box). The central line represents the distribution median, boxes span 25th to 75th percentiles,
and error bars extend from 10th to 90th percentiles. * = p <0.006.
Pagnini et al. Pediatric Rheumatology 2014, 12:47 Page 7 of 9
http://www.ped-rheum.com/content/12/1/47activities were measured. A statistically significant increase
of anti-Xa activity in the mothers studied was shown,
while there was no detection of anti-IIa and anti-Xa activ-
ities in fetus. It was therefore concluded that enoxaparin
does not cross the placenta and appeared to be safe for
the fetuses. However, such studies and others [8,35]
measured only heparin activity in fetal plasma, and not
direct drug presence. We were able to retrieve dried
blood spots taken at birth from children whose mothers
were administered with LMWH during pregnancy, and
could investigate the possible presence of heparin with a
new liquid chromatography tandem mass spectrometry
method. Tandem mass spectroscopy performed on DBS
failed to determine traces of heparin in newborn blood,
thus confirming its fetal safety. With regard to corticoste-
roids, although a fetal effect of high-dose prednisone
cannot be excluded, it is known that the fetus is pro-
tected from the effect of prednisone because of the
placental enzyme 11-β-dehydrogenase, which oxidizes it
into an inactive form.
In order to assess bone status, we performed phalan-
geal QUS, since it is a noninvasive method that provides
a surrogate estimation not only of bone density, but also
of bone elasticity and architecture, with specific parame-
ters derived from sound waves passing through both
cortical and trabecular bone [36-38]. The measurementsite chosen was the hand phalanges, which are com-
posed of predominantly cortical bone and are easily
accessibile [39]. Although it is known that dual X-ray
absorptiometry (DXA) is gold standard in order to asses
bone density, its use in the pediatric age is hampered by
the need to sedate young children and by radiation dose,
albeit minimal. Moreover, we and others have shown a
good correlation between ultrasound and DXA in
pediatric rheumatic diseases [40-43].
Despite the fact that phalangeal QUS measurements
have shown the ability to reveal changes due to skeletal
growth [44], it is known that bone density values can arti-
ficially be modified by bone or body size. Hence, we have
transformed QUS results by correcting centile values by
BMI, which takes into account both height and weight. In
our statistical analysis we have considered all factors that
could be confounders for reduced bone density, such as
birth weight [20], gender [18], intrauterine complications
[5], prematurity, vitamin D supplementation and levels. In
the multivariate analysis only age at examination resulted
the single predictor of QUS values, in that older children
had mostly normal values while younger infants did not.
In particular, not only drugs did not seem to pass the
placenta but also they were not linked to a low bone mass.
We hypothesize that mothers with autoimmune systemic
diseases are at risk for delivering babies with low bone
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these children with regard to their bone health seems to be
good, since when tested during late childhood or preado-
lescence bone ultrasound values were in the normal range.
We acknowledge the limit of the lack of a control group;
however, QUS values for healthy children have already
been obtained by our laboratory and did correlate with the
reference values from the manufacturer that we have used.
In addition, we did not have bone marker values from age-
matched healthy controls, but most of the results in our
series were already in the normal range provided by our
laboratory, hence ruling out the possibility of false positives
due to high bone turnover in a growing skeleton.
Conclusions
In conclusion, our study suggests that children born from
mothers with autoimmune diseases are at risk for low bone
mass during the first years of life, and shows that this risk
is not linked to exposure to potentially osteotoxic drugs.
Moreover, we have confirmed for the first time with a
direct assay that LMWHs do not cross the placental barrier.
Abbreviations
PAPS: Primary antiphospholipid syndrome; SLE: Systemic lupus
erythematosus; UCTD: Undifferentiated connective tissue disease;
MCTD: Mixed connective tissue disease; RA: Rheumathoid arthritis;
IVIG: intravenous immunoglobulins; ANA: Antinuclear antibodies;
ENA: Extractable nuclear antigens; ANCA: Antineutrophil cytoplasmic
antibodies; LAC: Lupus anticoagulant; aCL: Anticardiolipin antibodies;
aPL: Antiphospholipid antibodies.
Competing interests
Pagnini Ilaria, Simoni Gabriele, Cavalli Loredana, La marca Giancarlo, Iuliano
Annamaria, Brandi Marialuisa, Bellisai Francesca, Frediani Bruno, Galeazzi
Mauro, Cantarini Luca and Cimaz Rolando: no competing interests.
The authors declare that they have no competing interests.
Authors’ contributions
All the authors has made intellectual contribution to the study. In particular:
PI, CL, IA and CR have made contributions to conception and design,
analyzed and interpretations of data. SG, LMG, BM and FB have been
involved in drafting and revising the manuscript. GM, IP, RC and CL have
given final approval of version to be published. All authors read and
approved the final manuscript.
Author details
1Department of Pediatrics, University of Florence, AOU Meyer, Rheumatology
Unit, Viale Pieraccini 24, 50139 Florence, Italy. 2Department of Endocrinology,
University of Florence, Florence, Italy. 3Department of Rheumatology,
Policlinico Le Scotte, University of Siena, Siena, Italy.
Received: 10 June 2014 Accepted: 16 September 2014
Published: 23 October 2014
References
1. Bazaan M, Donvito V: Low-molecular-weight heparin during pregnancy.
Throm Res 2001, 1:175–186.
2. Ruitz-Irastorza G, Khamashta Munther A: Management of thrombosis in
antiphospholipid syndrome and systemic lupus erythematosus in
pregnancy. Ann N Y Acad Sci 2005, 1051:606–612.
3. Tuthill JI, Khamashta MA: Management of antiphospholipid syndrome.
J Autoimmun 2009, 33:92–98.
4. Cooper C, Westlake S, Harvey N, Javaid K, Dennison E, Hanson M: Review:
developmental origins of osteoporotic fracture. Osteoporosis Int 2006, 17:337–347.5. Gale CR, Martyn CN, Kellingray S, Eastell R, Cooper C: Intrauterine programming
of adult body composition. J Clin Endocrinol Metab 2001, 86:267–272.
6. McGuigan FE, Murray L, Gallagher A, Davey-Smith G, Neville CE, Van't Hof R,
Boreham C, Ralston SH: Genetic and environmental determinants of peak
bone mass in young men and women. J Bone Mineral Res 2002, 17:1273–1279.
7. Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin
and aspirin plus heparin in pregnant women with recurrent miscarriage
associated with phospholipid antibodies. BMJ 1997, 314:253–257.
8. Deruelle P, Coulon C: The use of low-molecular-weight heparins in
pregnancy- how safe are they? Curr Opin Obstet Gynecol 2007, 19:573–577.
9. Rowan JA, McLintock C, Taylor RS, North RA: Prophylactic and therapeutic
enoxaparin during pregnancy: indications, outcomes and monitoring.
Aust N Z J Obstet Gynaecol 2003, 43:123–128.
10. Huxtable LM, Tafreshi MJ, Ondreyco SM: A protocol for the use of
enoxaparin during pregnancy: results from 85 pregnancies including 13
multiple gestation pregnancies. Clin Appl Thromb Hemost 2005, 11:171–181.
11. Mok GC, Wong RWS: Pregnancy in systemic lupus erythematosus.
Postgrad Med J 2001, 77:157–165.
12. Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N,
Michalas S: Absence of transplacental passage of the low molecular
weight heparin enoxaparin. Haemostasis 2000, 30:243–248.
13. Wuster C, Albanese C, DeAloysio D, Duboeuf F, Gambacciani M, Gonnelli S,
Glüer CC, Hans D, Joly J, Reginster JY, De Terlizzi F, Cadossi R: Phalangeal
osteosonogrammetry study: age-related changes, diagnostic sensitivity,
and discrimination power. The Phalangeal Osteosonogrammetry Study
Group. J Bone Miner Res 2000, 15:1603–1614.
14. Benitez CL, Schneider DL, Barret-Connor E, Sartoris DJ: Hand ultrasound for
osteoporosis screening in postmenopausal women. Osteoporos Int 2000,
11:203–210.
15. Cadossi R, Cane V: Pathways of transmission of ultrasound energy
through the distal metaphysics of the second phalanx of pigs: an
in vitro study. Osteoporosis Int 1996, 6:196–206.
16. Auray-Blais C, Bhérer P, Gagnon R, Young SP, Zhang HH, An Y, Clarke JT,
Millington DS: Efficient analysis of urinary glycosaminoglycans by LC-MS/MS
in mucopolysaccharidoses type I, II and VI. Mol Genet Metab 2011, 102:49–56.
17. Javad MK, Cooper C: Prenatal and childhood influences on osteoporosis.
Best Pract Res Clin Endocrinol Metab 2002, 16:349–367.
18. Eriksson JG, Kajante E, Osmond C, Thornburg K, Barker DJ: Boys life
dangerously in the womb. Am J Hum Biol 2010, 22:330–335.
19. Cooper C, Harvey N, Javaid K, Hanson M, Dennison E: Nestle Nutr Workshop
Ser Pediatric Program 2008, 61:53–68.
20. Baird J, Kurshid MA, Kim M, Harvey N, Dennison E, Cooper C: Does
birthweight predict bone mass in adulthood? A systemic review and
meta-analysis. Osteoporos Int 2011, 22:1323–1334.
21. Lin P, Bonaminio P, Ramsey-Goldamn R: Pregnancy And Rheumatic Disease.
In Current Rheumatology Diagnosis And Treatment. secondth edition. Edited by
Imboden J, Hellmann D, Stone J. USA: McGraw-Hill Companies, Inc; 2007:146–159.
22. Bear AN, Witter FR, Petri M: Lupus and pregnancy. Obstet Gynecol Surv
2011, 66:639–653.
23. Kher A, Bausersache R, Nielsen JD: The management of thrombosis in
pregnancy: role of low-molecular weight heparin. Thromb Haemost 2007,
97:505–513.
24. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG: The effects of heparin and
low molecular weight heparins on bone. Thromb Res 2008, 122:293–298.
25. Rodger MA, Kahn SR, Cranney A, Hodsman A, Kovacs MJ, Clement AM, Lazo-
Langner A, Hague WM, TIPPS investigators: Long-term dalteparin in
pregnancy not associated with a decrease in bone mineral density: substudy
of a randomized controlled trial. J Thromb Haemost 2007, 5:1600–1606.
26. Michalakis K, Peitsidis P, Ilias I: Pregnancy- and lactation-associated
osteoporosis: a narrative mini-review. Endocr Regul 2011, 45:43–47.
27. Choe EY, Song JE, Park KH, Seok H, Lee EJ, Lim SK, Rhee Y: Effect of teriparatide
on pregnancy and lactation-associated osteoporosis with multiple vertebral
fractures. J Bone Miner Metab 2011, 23: [Epub ahead of print].
28. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E,
Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamulyák K,
Theunissen IM, Hunt BJ, Büller HR: Safety of low-molecular weight heparin in
pregnancy: a systematic review. Thromb Haemost 1999, 81:668–672.
29. Greer IA, Nelson-Piercy C: Low-molecular-weight heparins for
thromboprophylaxis and treatment of venous thromboembolism in
pregnancy: a systematic review of safety and efficacy. Blood 2005,
106:401–407.
Pagnini et al. Pediatric Rheumatology 2014, 12:47 Page 9 of 9
http://www.ped-rheum.com/content/12/1/4730. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD,
Nicolaides KH, Barrett JJ, Kakkar VV: Use of low molecular weight heparin
in pregnancy. Thromb Haemost 1992, 68:652–656.
31. Forestier F, Daffos E, Capell-pavlovsky M: Low molecular weight heparin
(PK 10169) does not cross the placenta during the second trimester of
pregnancy. Study by direct fetal blood sampling under ultrasound.
Thromb Res 1984, 34:557–560.
32. Omri A, Delaloye JF, Bachmann F: Low molecular weight heparin novo
(LHN-1) does not cross the placenta during the second trimester of
pregnancy. Thromb Haemostas 1989, 61:55–56.
33. Forestier F, Daffos F, Rainauut M, Toulemonde F: Low molecular weight
heparin (CY216) does not cross the placenta during the third trimester
of pregnancy. Thromb Haemostas 1987, 57:234.
34. Andrew M, Boneu B, Cade J, Cerskus AL, Hirsh J, Jefferies A, Towell ME,
Buchanan MR: Placental transport of low molecular weight heparin in the
pregnant sheep. Br J Haematol 1985, 59:103–108.
35. Mätzsch T, Bergqvist D, Bergqvist A, Hodson S, Dawes J, Hedner U,
Ostergaard P: No transplacental passage of standard heparin or an
enzymatically depolymerized low molecular weight heparin. Blood
Coagul Fibrinolysis 1991, 2:273–278.
36. Kaufman JJ, Einhorn TA: Perspective: ultrasound assessment of bone.
J Bone Miner Res 1993, 8:517–525.
37. Genant HK, Engleke K, Fuerst T, Glüer CC, Grampp S, Harris ST, Jergas M, Lang
T, Lu Y, Majumdar S, Mathur A, Takada M: Noninvasive assessment of bone
mineral and structure: state of the art. J Bone Miner Res 1996, 11:707–730.
38. Glüer CC: Quantitative ultrasound techniques for the assessment of
osteoporosis: expert agreement on current status. J Bone Miner Res 1997,
12:1280–1288.
39. Mann TS, McGregor AH, Patel R: The correlation between phalangeal
quantitative ultrasonography and dual energy X-ray absorptiometry in
women with premature ovarian failure. Mcgill J Med 2008, 11:132–140.
40. Falcini F, Bindi G, Ermini M, Galluzzi F, Poggi G, Rossi S, Masi L, Cimaz R,
Brandi ML: Comparison of quantitative calcaneal ultrasound and dual
energy X-ray absorptiometry in the evaluation of osteoporotic risk in
children with chronic rheumatic diseases. Calcif Tissue Int 2000, 67:19–23.
41. Simonini G, Cimaz R, Falcini F: Usefulness of bone ultrasound techniques
in pediatric rheumatic diseases. J Reumatol 2005, 32:198–199.
42. Hartman C, Shamir R, Eshach-Adiv O, Iosilevsky G, Brik R: Assessment of
osteoporosis by quantitative ultrasound versus dual energy X-ray
absorptiometry in children with chronic rheumatic diseases. J Rheumatol
2004, 31:981–985.
43. Njeh CF, Shaw N, Gardner-Medwin JM, Boivin CM, Southwood TR: Use of
quantitative ultrasound to assess bone status in children with juvenile
idiopathic arthritis: a pilot study. J Clin Densitom 2001, 3:251–260.
44. Halaba Z, Pluskiewicz W: The assessment of development of bone mass
in children by quantitative ultrasound through the proximal phalanxes
of the hand. Ultrasound Med Biol 1997, 23:1331–1335.
doi:10.1186/1546-0096-12-47
Cite this article as: Pagnini et al.: Bone status of children born from
mothers with autoimmune diseases treated during pregnancy with
prednisone and/or low molecular weight heparin. Pediatric Rheumatology
2014 12:47.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
